Auteur M. EVANS-BROWN

  Tris disponibles Ajouter le résultat à votre sélection

  Affiner la recherche

Assessing the toxicological significance of new psychoactive substances in fatalities

S. ELLIOTT ; R. SEDEFOV ; M. EVANS-BROWN | 2018
Dans Drug Testing and Analysis (Vol.10, n°1, January 2018) Article : Périodique

The number of new psychoactive substances (NPS) has increased significantly, especially within the last 5 years. The EMCDDA conducts risks assessments of such substances, especially in relation to serious adverse events. Examination of the indiv[...]

Plus d'info

Ajouter à la sélection

Lien externe

Continued signs of resilience in the European drug market: Highlights from the EMCDDA's 2016 European drug report

J. MOUNTENEY ; P. GRIFFITHS ; A. CUNNINGHAM ; M. EVANS-BROWN ; M. FERRI ; D. HEDRICH ; A. NOOR | 2016
Dans Drugs: Education, Prevention and Policy (Vol.23, n°6, December 2016) Article : Périodique

May 2016 saw the launch of the European Drug Report (EDR), the European Monitoring Centre for Drugs and Drug Addiction's (EMCDDA) annual review of the European drug situation, incorporating situational and trend analysis, statistical data and in[...]

Plus d'info

Ajouter à la sélection

EMCDDA operating guidelines for the European Union Early Warning System on new psychoactive substances

OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. SEDEFOV | 2019
Rapport

These guidelines provide the rationale, steps, procedures, roles, and responsibilities for the operation of the EU Early Warning System. They reflect the requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 20[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation. An update from the EU Early Warning System

OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. CHRISTIE ; S. SOLA ; A. ALMEIDA ; R. JORGE ; J. DE MORAIS ; R. SEDEFOV | 2018
Rapport

In this update from the EU Early Warning System, the EMCDDA aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency's early warning and risk-assessment activities. This report cov[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Fentanyl in Europe: EMCDDA Trendspotter study

OEDT = EMCDDA ; J. MOUNTENEY ; M. EVANS-BROWN ; I. GIRAUDON | 2012
Rapport

The EMCDDA Trendspotter case study on Fentanyl in Europe was undertaken during September and October 2012. It culminated in an expert meeting in Lisbon on 9-10 October 2012. The aim of the study was to increase understanding of the availability [...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age [Editorial]

P. GRIFFITHS ; M. EVANS-BROWN ; R. SEDEFOV | 2013
Dans Addiction (Vol.108, n°10, October 2013) Article : Périodique

There is a need to review the various regulatory options that are available in order to address the challenge presented by a plethora of new psychoactive substances appearing on the market as well as to address the technology for rapid developme[...]

Plus d'info

Ajouter à la sélection

Lien externe

Hexahydrocannabinol (HHC) and related substances

OEDT = EMCDDA ; I. UJVARY ; M. EVANS-BROWN ; A. GALLEGOS ; G. PLANCHUELO ; J. DE MORAIS ; R. CHRISTIE ; R. JORGE ; R. SEDEFOV | 2023
Rapport

The markets for hexahydrocannabinol (HHC) and related semi-synthetic cannabinoids (SSC) are rapidly evolving areas with relatively limited information currently available. The European situation presented in Section 1 can only provide an overvie[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Injecting human growth hormone as a performance-enhancing drug - perspectives from the United Kingdom

M. EVANS-BROWN ; J. McVEIGH | 2009
Dans Journal of Substance Use (Vol.14 n°5, 2009) Article : Périodique

ENGLISH : Injectable human growth hormone has been used as a performance-enhancing drug in the United Kingdom since at least the mid-1980s. However, because of its prohibitive cost and limited supply it was initially restricted to a relatively[...]

Plus d'info

Ajouter à la sélection

Isotonitazene. Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. SEDEFOV ; A. ALMEIDA ; R. CHRISTIE ; P. DUQUE ; A. GALLEGOS ; R. JORGE ; J. DE MORAIS | 2020
Rapport

This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on [...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

New benzodiazepines in Europe - a review

OEDT = EMCDDA ; V. AUWÄRTER ; J. DE MORAIS ; A. GALLEGOS ; M. EVANS-BROWN ; R. CHRISTIE ; R. JORGE ; R. SEDEFOV | 2021
Rapport

This report provides a technical review of the current body of knowledge regarding new benzodiazepines that are monitored by the EU Early Warning System. The aims of this report are to strengthen situational awareness of new benzodiazepines in E[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System

OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; R. CHRISTIE ; R. JORGE ; J. DE MORAIS ; A. ALMEIDA ; R. SEDEFOV | 2020
Rapport

In this update from the the EU Early Warning System aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency's early warning and risk-assessment activities. The report covers the p[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

New psychoactive substances in Europe. An update from the EU Early Warning System (March 2015)

OEDT = EMCDDA ; M. EVANS-BROWN ; A. GALLEGOS ; W. FRANCIS ; R. CHRISTIE ; A. CUNNINGHAM ; J. SEKULA ; A. ALMEIDA ; R. SEDEFOV | 2015
Rapport

FRANÇAIS : De nouvelles substances psychoactives (NSP ou «nouvelles drogues») ont été détectées dans l'Union européenne l'année dernière au rythme de deux par semaine environ. Au total, 101 nouvelles substances ont été signalées au système d'al[...]

Plus d'info

Ajouter à la sélection

Lien externe

Documents numériques

New psychoactive substances in Europe: Innovative legal responses

OEDT = EMCDDA ; B. HUGHES ; M. EVANS-BROWN | 2015
Rapport

This short report provides an overview of how European countries are developing innovative legal responses to the challenges presented to public health and drug policy by the rapidly evolving market for new psychoactive substances.

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

Recreational use of nitrous oxide: a growing concern for Europe

OEDT = EMCDDA ; L. VAN AERTS ; J. DE MORAIS ; M. EVANS-BROWN ; R. JORGE ; A. GALLEGOS ; R. CHRISTIE ; T. NÉFAU ; G. PLANCHUELO ; R. SEDEFOV | 2022
Rapport

The purpose of this report is to examine the current situation, risks and responses to the recreational use of nitrous oxide in Europe. To support this, the report also provides a state-of-the-art review of the chemistry, pharmacology and toxico[...]

Plus d'info

Ajouter à la sélection

Lien externe

Document numérique

A summary of the health harms of drugs

L. JONES ; G. BATES ; M. BELLIS ; C. BEYNON ; P. DUFFY ; M. EVANS-BROWN ; A. J. MACKRIDGE ; E. McCOY ; H. SUMNALL ; J. McVEIGH | 2011
Rapport

FRANÇAIS : Ce rapport s'intéresse aux dommages sur la santé physique et mentale causés par la consommation de drogues. Il prend principalement la forme de tableaux donnant, pour chacune des substances étudiées, les effets liés à une consommatio[...]

Plus d'info

Ajouter à la sélection

Lien externe